GSK plc 6-K, filed May 27, 2022
GSK plc (GSK)
6-K
2022-05-27
For: 2022-05-26
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 27, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 27 May 2022, London UK
China
approves Cervarix two-dose
vaccine schedule for girls aged 9 to 14 against certain types of
cancer-causing human papillomavirus
●
China's
National Medical Products Administration (NMPA) has approved a
two-dose vaccine schedule for Cervarix in
girls aged between 9 to 14 years for the prevention of cervical
cancer, cervical intraepithelial neoplasia and adenocarcinoma in
situ causally related to oncogenic
Human Papillomavirus (HPV) types
16 and 18
●
In
2020, there were approximately 110,000 new cases of cervical cancer
and 59,000 deaths due to the disease in China1
GSK plc (LSE/NYSE: GSK) announced today that a two-dose schedule
for its HPV vaccine Cervarix [Human Papillomavirus bivalent (types 16,
18) Vaccine, Recombinant)] has been approved by China's NMPA for
girls aged 9 to 14. With this approval, Cervarix is the first imported two-dose HPV vaccine
for this age group in mainland China.
The NMPA authorisation of the two-dose regimen adds China to
two-dose approvals in approximately 100 countries, including the
European Union, Asia, Africa, and Latin America2-7.
The three-dose schedule remains on the label for girls and women
aged 15-45 years in China.
About cervical cancer
Cervical cancer has the highest mortality of all malignant tumours
in the female reproductive system in China1,
with 110,000 new cases of cervical cancer and 59,000 deaths due to
the disease. Incidence and mortality rates show an increasing trend
in younger women8.
The potential impact of vaccines against oncogenic HPV types 16 and
18 is estimated to be high (84.5%) against total squamous cell
carcinoma (SCC).9
Vaccination with HPV vaccine in the female population at
appropriate ages may significantly reduce the morbidity of cervical
cancer and precancerous lesions, thereby reducing the burden of the
disease. HPV is predominately transmitted through sexual contact;
the primary target population for HPV vaccination is girls aged
9-14 years who have not yet had sex. With a two-dose schedule, more
girls could be vaccinated against HPV, leading to the protection of
more women against HPV-related cervical cancer.
About Cervarix
Cervarix (Human
Papillomavirus vaccine Types 16 and 18 [Recombinant, AS04
adjuvanted]) is a non-infectious recombinant, AS04-adjuvanted
vaccine. Cervarix demonstrated direct evidence of lowering
cervical cancer incidence rates10.
A register-based study in England where girls were offered the
vaccine in school year eight (aged 12 to 13 years), had an 87%
reduction for cervical cancer and 97% reduction for precancerous
lesions (cervical intraepithelial neoplasia, CIN, grade 3); a more
significant effect than expected based on the incidence of HPV
16/18 strains (68%) included in the vaccine10. Cervarix has
also shown to be effective 93·2% (78·9-98·7) against
all CIN3+, irrespective of HPV type in the lesion and including
lesions with no HPV 16/18 DNA detected, suggesting a wider than HPV
16/18 benefit.11
About GSK
GSK is a science-led global healthcare company. For further
information, please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
Reference:
1. Chen
WQ, Zheng RS, Baade PD,et al. Cancer
Statistics in China, 2015. CA CANCER J CLIN 2016;
00:00-00:1-18
2. GSK.
GSK Cervarix® two-dose
schedule receives European marketing authorisation
https://www.gsk.com/en-gb/media/press-releases/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation/
3. Lyseng-Williamson,
K.A., Human papillomavirus-16/18 AS04-adjuvanted vaccine
(Cervarix®): a guide to its two-dose schedule in girls
aged 9-14 years in the EU. Paediatr Drugs, 2014. 16(3): p.
247-53.
4.
Tay, S.K., et al., Cost-effectiveness of two-dose human
papillomavirus vaccination in Singapore. Singapore Med J, 2018.
59(7): p. 370-382.
5.
Germar, M.J., et al., Cost-effectiveness analysis of
AS04-adjuvanted human papillomavirus 16/18 vaccine compared with
human papillomavirus 6/11/16/18 vaccine in the Philippines, with
the new 2-dose schedule. Hum Vaccin Immunother, 2017. 13(5): p.
1158-1166.
6.
Van Kriekinge, G., et al., Comparative Cost-Effectiveness Analysis
of Two Different Two-Dose Human Papillomavirus Vaccines in
Malaysia. Asian Pac J Cancer Prev, 2018. 19(4): p.
933-940.
7.
GSK. GSK internal tracking system for Global Regulatory
Affairs.
8.
Liuye Huang, Xuelian Zhao,Fanghui Zhao.Trends in incidence and
mortality of cervical cancer and progress in its prevention
strategies[J]. Electronic Journal of Comprehensive Cancer Therapy,
2021
9.
Chen, W., et al., Human papillomavirus type-distribution in
cervical cancer in China: the importance of HPV 16 and 18. Cancer
Causes Control, 2009. 20(9): p. 1705-13.
10.
Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K,
Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the
national HPV vaccination programme in England, UK, on cervical
cancer and grade 3 cervical intraepithelial neoplasia incidence: a
register-based observational study. Lancet. 2021 Nov
3:S0140-6736(21)02178-4.
11. Lehtinen
M, Paavonen J, Wheeler CM, et al. Overall
efficacy of HPV 16/18 AS04-adjuvanted vaccine against grade 3 or
greater cervical intraepithelial neoplasia: 4-year end-of-study
analysis of the randomised, double-blind PATRICIA trial - Web
appendix. Lancet Oncol 2012; 13: 89-99.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
27, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|